Antibiotics for acute pyelonephritis in children

Area of Science:

• Pediatric infectious diseases
• Clinical pharmacology
• Evidence-based medicine

Background:

• Urinary tract infections (UTIs) are common in infants, with acute pyelonephritis being the most severe form.
• Acute pyelonephritis can lead to significant morbidity and potential permanent kidney damage.
• Current guidelines recommend initial intravenous (IV) antibiotic therapy followed by oral therapy for 7-14 days, but optimal duration lacks consensus.

Purpose of the Study:

• To evaluate the benefits and harms of various antibiotic regimens for treating acute pyelonephritis in pediatric patients.
• To compare different antibiotic agents, routes of administration, dosing frequencies, and treatment durations.

Main Methods:

• Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
• Searched multiple databases (Cochrane Register, MEDLINE, EMBASE) and reference lists.
• Included trials involving children aged 0-18 years with confirmed UTI and acute pyelonephritis.

Main Results:

• No significant difference in persistent renal damage at six months between 14-day oral cefixime and 3-day IV followed by 10-day oral therapy.
• No significant difference in persistent renal damage between short-course (3-4 days) IV followed by oral therapy and 7-14 day IV therapy.
• No significant difference in efficacy between daily and thrice-daily aminoglycoside administration.

Conclusions:

• Children with acute pyelonephritis can be effectively treated with oral cefixime or short-course IV therapy (2-4 days) followed by oral antibiotics.
• Single daily dosing of aminoglycosides is a safe and effective IV option.
• Further trials are needed to establish optimal total therapy duration and explore other oral antibiotics for initial treatment.